Biotech News
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
Emergent’s Canton facility will manufacture drug substance and obtains exclusive distribution rights GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an agreement with Substipharm Biologics valued at
